Johnson & Johnson

5 hours ago · zacks.com

J&J's Caplyta shows rapid and significant improvement in bipolar mania symptoms in a pivotal phase III study.

1 day ago · benzinga.com

Johnson & Johnson (NYSE:JNJ) on Monday reported topline results from its Phase 3 study evaluating Caplyta (lumateperone) for adults experiencing manic episodes linked to bipolar I disorder.

1 day ago · reuters.com

Johnson & Johnson said on Monday its experimental use of Caplyta for bipolar mania met the main goal ​of a late-stage study, bringing the drug a step ‌closer to expanding beyond its currently approved uses.

2 days ago · 247wallst.com

Retirement portfolios need income that shows up on time, grows faster than inflation, and does not blink during a downturn.

4 days ago · zacks.com

JNJ's growth gets a boost from new drug launches and pipeline wins, but Stelara's patent loss and MedTech headwinds remain key risks.

4 days ago · zacks.com

In the most recent trading session, Johnson & Johnson (JNJ) closed at $270.22, indicating a +1.1% shift from the previous trading day.

4 days ago · seekingalpha.com

Johnson & Johnson (JNJ) Presents at Deutsche Bank 2026 Healthcare Summit Transcript

5 days ago · marketbeat.com

Johnson & Johnson NYSE: JNJ Executive Vice President and Chief Financial Officer Joe Wolk said the company sees a path to growth above its previously stated 5% to 7% long-term range, supported by its pharmaceutical pipeline, medical technology portfolio and capital flexibility.

6 days ago · gurufocus.com

Johnson and Johnson (JNJ), the pharmaceutical and medical-technology giant, added another potentially important commercial argument for Caplyta, with new late-sta

6 days ago · 247wallst.com

Realty Income pays you every month while Johnson and Johnson barely clears 2% yield, yet one of these retirement staples is quietly demolishing the other where it counts most for a 20-year income plan.